Trials that use: Multiplicity adjustment
New to this method? Read the tutorial →
20,317 results
- Testing Integrative Smoking Cessation for HIV Patients: Complete Statistical AnalysisIndependent statistical analysis of Testing Integrative Smoking Cessation for HIV Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05030766).
- Testing Intervention Strategies for Addressing Obesity and Binge Eating: Complete Statistical AnalysisIndependent statistical analysis of Testing Intervention Strategies for Addressing Obesity and Binge Eating: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04771455).
- Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH – Subprotocol Z1K): Complete Statistical AnalysisIndependent statistical analysis of Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1): Complete Statistical AnalysisIndependent statistical analysis of Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Testing Legally Feasible Options Studies 2/3: Complete Statistical AnalysisIndependent statistical analysis of Testing Legally Feasible Options Studies 2/3: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05604508).
- Testing Multiple Behavioral Science Strategies to Increase Flu-Shot Rates: Complete Statistical AnalysisIndependent statistical analysis of Testing Multiple Behavioral Science Strategies to Increase Flu-Shot Rates: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04565353).
- Testing New Ways to Name Antimicrobial Resistance: Complete Statistical AnalysisIndependent statistical analysis of Testing New Ways to Name Antimicrobial Resistance: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06356285).
- Testing of a Valsalva Assist Device (VAD) in Healthy Volunteers Performing a Valsalva Manoeuvre: Complete Statistical AnalysisIndependent statistical analysis of Testing of a Valsalva Assist Device (VAD) in Healthy Volunteers Performing a Valsalva Manoeuvre: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors: Complete Statistical AnalysisIndependent statistical analysis of Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03878095).
- Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients: Complete Statistical AnalysisIndependent statistical analysis of Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH – Subprotocol Z1C): Complete Statistical AnalysisIndependent statistical analysis of Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C): primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Testing the Ability of JNJ-18038683 to Improve Cognition and Reduce Depressive Symptoms in Stable Bipolar Patients: Complete Statistical AnalysisIndependent statistical analysis of Testing the Ability of JNJ-18038683 to Improve Cognition and Reduce Depressive Symptoms in Stable Bipolar Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC): Complete Statistical AnalysisIndependent statistical analysis of Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC): primary endpoint results,…
- Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer,…
- Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment: Complete Statistical AnalysisIndependent statistical analysis of Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment…
- Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors: Complete Statistical AnalysisIndependent statistical analysis of Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors: primary endpoint results, effect estimate with confidence interval,…
- Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial: Complete Statistical AnalysisIndependent statistical analysis of Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma: Complete Statistical AnalysisIndependent statistical analysis of Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma: primary endpoint results,…
- Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval,…
- Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial: Complete Statistical AnalysisIndependent statistical analysis of Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone: Complete Statistical AnalysisIndependent statistical analysis of Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the…
- Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma: Complete Statistical AnalysisIndependent statistical analysis of Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma: primary endpoint results, effect…
- Testing the Effectiveness of a Falls Prevention System: Complete Statistical AnalysisIndependent statistical analysis of Testing the Effectiveness of a Falls Prevention System: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03678402).
- Testing the Effectiveness of Telephone-based Early Childhood Developmental Screening: Complete Statistical AnalysisIndependent statistical analysis of Testing the Effectiveness of Telephone-based Early Childhood Developmental Screening: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02495025).
- Testing the Effects of Palbociclib and Fulvestrant or Letrozole for Patients 70 Years of Age of Older With Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Testing the Effects of Palbociclib and Fulvestrant or Letrozole for Patients 70 Years of Age of Older With Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence…
- Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer: Complete Statistical AnalysisIndependent statistical analysis of Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian,…
- Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial): Complete Statistical AnalysisIndependent statistical analysis of Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial): primary endpoint results, effect estimate with…
- Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma: Complete Statistical AnalysisIndependent statistical analysis of Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma:…
- Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH – Subprotocol J): Complete Statistical AnalysisIndependent statistical analysis of Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J): primary endpoint results, effect estimate…
- Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer: primary endpoint results, effect estimate with confidence interval,…
- Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study: Complete Statistical AnalysisIndependent statistical analysis of Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer: Complete Statistical AnalysisIndependent statistical analysis of Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Testopel ® vs. Generic Testosterone Pellets.: Complete Statistical AnalysisIndependent statistical analysis of Testopel ® vs. Generic Testosterone Pellets.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04523480).
- Testosterone Gel in Preventing Weakness Caused by Steroid Therapy in Men With Glioma: Complete Statistical AnalysisIndependent statistical analysis of Testosterone Gel in Preventing Weakness Caused by Steroid Therapy in Men With Glioma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Testosterone Replacement for Fatigue in Male Hypogonadic Advanced Cancer Patients: Complete Statistical AnalysisIndependent statistical analysis of Testosterone Replacement for Fatigue in Male Hypogonadic Advanced Cancer Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00965341).
- Testosterone Replacement in Men With Diabetes and Obesity: Complete Statistical AnalysisIndependent statistical analysis of Testosterone Replacement in Men With Diabetes and Obesity: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01127659).
- Tetra-NIRS Clinical Study: Complete Statistical AnalysisIndependent statistical analysis of Tetra-NIRS Clinical Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00871975).
- Tetracaine Versus Lidocaine Gel for Anesthetic Effect and Comfort in Patients Undergoing LASIK: Complete Statistical AnalysisIndependent statistical analysis of Tetracaine Versus Lidocaine Gel for Anesthetic Effect and Comfort in Patients Undergoing LASIK: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Tetracycline as a Prophylaxis for Rash in Patients With NSCLC Receiving Treatment With BIBW2992 (Afatinib): Complete Statistical AnalysisIndependent statistical analysis of Tetracycline as a Prophylaxis for Rash in Patients With NSCLC Receiving Treatment With BIBW2992 (Afatinib): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Tetrahydrobiopterin in Patients With Chronic Kidney Disease (CKD) and Albuminuria: Complete Statistical AnalysisIndependent statistical analysis of Tetrahydrobiopterin in Patients With Chronic Kidney Disease (CKD) and Albuminuria: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00625820).
- Tetrahydrobiopterin Treatment in Children With Idiopathic Cognitive Developmental Disorders: Complete Statistical AnalysisIndependent statistical analysis of Tetrahydrobiopterin Treatment in Children With Idiopathic Cognitive Developmental Disorders: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01141595).
- TEXTIndependent statistical analysis of Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Text Message Intervention for Alcohol Use and Sexual Violence in College Students: Complete Statistical AnalysisIndependent statistical analysis of Text Message Intervention for Alcohol Use and Sexual Violence in College Students: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- TEXT-TKRIndependent statistical analysis of A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement Surgery: primary endpoint results, effect estimate with…
- Text&TalkIndependent statistical analysis of Text and Talk: A Multi-level Intervention to Increase Provider HPV Vaccine Recommendation Effectiveness: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- TextFluenza: Using Technology To Promote Flu Vaccination In Underserved Maternal And Child Populations: Complete Statistical AnalysisIndependent statistical analysis of TextFluenza: Using Technology To Promote Flu Vaccination In Underserved Maternal And Child Populations: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Texting to Promote Breastfeeding (TOPS): Complete Statistical AnalysisIndependent statistical analysis of Texting to Promote Breastfeeding (TOPS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06375655).
- TExTMEDFANSIndependent statistical analysis of Harnessing mHealth and Social Support to Improve Diabetes Related Health Behavior for Inner-city Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Texture Analysis for Postmenopausal Osteoporosis: Complete Statistical AnalysisIndependent statistical analysis of Texture Analysis for Postmenopausal Osteoporosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00145977).